

**ANNEX I**  
**SUMMARY OF PRODUCT CHARACTERISTICS**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Melovem 5 mg/ml solution for injection for cattle and pigs

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

### Active substances:

Meloxicam 5 mg

### Excipients:

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Benzyl alcohol	50 mg
Hydrochloric acid	
Meglumine	
Macrogol 400	
Macrogol 1500	
Sodium chloride	
Water for injections	

Clear, greenish yellow solution.

## 3. CLINICAL INFORMATION

### 3.1 Target species

Cattle (calves and young cattle) and pigs.

### 3.2 Indications for use for each target species

#### Cattle:

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.

For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.

For the relief of post-operative pain following dehorning in calves.

#### Pigs:

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.

For the relief of post-operative pain associated with minor soft tissue surgery such as castration.

### 3.3 Contraindications

Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.

Do not use in pigs less than 2 days old.

### 3.4 Special warnings

Treatment of calves with the veterinary medicinal product 20 minutes before dehorning reduces post-operative pain. The veterinary medicinal product alone will not provide adequate pain relief during the dehorning procedure. To obtain adequate pain relief during surgery co-medication with an appropriate analgesic is needed.

Treatment of piglets with the veterinary medicinal product before castration reduces post-operative pain. To obtain pain relief during surgery co-medication with an appropriate anaesthetic/sedative is needed.

To obtain the best possible pain relieving effect post-surgery the veterinary medicinal product should be administered 30 minutes before surgical intervention.

### 3.5 Special precautions for use

#### Special precautions for safe use in the target species:

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in very severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Accidental self-injection may give rise to pain. People with known hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

#### Special precautions for the protection of the environment:

Not applicable.

### 3.6 Adverse events

Cattle and pigs:

Common (1 to 10 animals / 100 animals treated):	Injection site pain <sup>1</sup> , Injection site swelling <sup>1</sup>
Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Anaphylactoid reaction <sup>2</sup>

<sup>1</sup> Transient

<sup>2</sup> May be serious (including fatal) and should be treated symptomatically.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### 3.7 Use during pregnancy, lactation or lay

#### Pregnancy and lactation:

Cattle:

Can be used during pregnancy.

Pigs:

Can be used during pregnancy and lactation.

### **3.8 Interaction with other medicinal products and other forms of interaction**

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.

### **3.9 Administration routes and dosage**

Cattle:

Single subcutaneous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 10 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.

Pigs:

Locomotor disorders:

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2 ml/25 kg body weight). If required, a second administration of meloxicam can be given after 24 hours.

It is recommended to administer the second injection at a different site since local tolerance has been assessed after single injection only.

Reduction of post-operative pain:

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 0.4 ml/5 kg body weight) before surgery.

Particular care should be taken with regard to the accuracy of dosing including the use of an appropriate dosing device and careful estimation of body weight.

Avoid introduction of contamination during use.

### **3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

In the case of overdosage symptomatic treatment should be initiated.

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

### **3.12 Withdrawal periods**

Cattle:

Meat and offal: 15 days.

Not authorised for use in animals producing milk for human consumption.

Pigs:

Meat and offal: 5 days.

## **4. PHARMACOLOGICAL INFORMATION**

### **4.1 ATCvet code: QM01AC06**

### **4.2 Pharmacodynamics**

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and antipyretic properties. Meloxicam also has anti-endotoxic properties because it has been shown to inhibit production of thromboxane B2 induced by *E. coli* endotoxin administration in calves and pigs.

### **4.3 Pharmacokinetics**

#### Absorption:

After a single subcutaneous dose of 0.5 mg meloxicam/kg,  $C_{max}$  values of 2.1 µg/ml were reached after 7.7 hours in young cattle.

Following single intramuscular doses of 0.4 mg meloxicam/kg, a  $C_{max}$  value of 1.1 to 1.5 µg/ml was reached within 1 hour in pigs.

#### Distribution:

More than 98% of meloxicam is bound to plasma proteins. The highest meloxicam concentrations are to be found in liver and kidney. Comparatively low concentrations are detectable in skeletal muscle and fat.

#### Metabolism:

Meloxicam is predominantly found in plasma. In cattle, meloxicam is also a major excretion product in milk and bile whereas urine contains only traces of the parent compound. In pigs, bile and urine contain only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.

#### Elimination:

Meloxicam is eliminated with a half-life of 26 hours after subcutaneous injection in young cattle.

In pigs, after intramuscular administration, the mean plasma biological elimination half-life is approximately 2.5 hours.

Approximately 50% of the administered dose is eliminated via urine and the remainder via faeces.

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

### **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.

Shelf life after first opening the immediate packaging: 28 days.

### **5.3 Special precautions for storage**

Keep the injection vial in the outer carton in order to protect from light.

This veterinary medicinal product does not require any special temperature storage conditions.

#### **5.4 Nature and composition of immediate packaging**

Cardboard box with 1 colourless, type I glass injection vial of 100 ml, which is closed with a bromobutyl rubber stopper and sealed with an aluminium cap.

#### **5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

### **6. NAME OF THE MARKETING AUTHORISATION HOLDER**

Dopharma Research B.V.

### **7. MARKETING AUTHORISATION NUMBER(S)**

EU/2/09/098/001

### **8. DATE OF FIRST AUTHORISATION**

Date of first authorisation: 07/07/2009.

### **9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

### **10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Melovem 20 mg/ml solution for injection for cattle, pigs and horses

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

### Active substances:

Meloxicam 20 mg

### Excipients:

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Ethanol	150 mg
Glycine	
Hydrochloric acid/sodium hydroxide	
Meglumine	
Macrogol 300	
Poloxamer 188	
Sodium citrate	
Water for injections	

Clear yellow solution.

## 3. CLINICAL INFORMATION

### 3.1 Target species

Cattle, pigs and horses.

### 3.2 Indications for use for each target species

#### Cattle:

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.

For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.

For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.

For the relief of post-operative pain following dehorning in calves.

#### Pigs:

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.

For adjunctive therapy in the treatment of puerperal septicaemia and toxæmia (mastitis-metritisagalactia syndrome) with appropriate antibiotic therapy.

#### Horses:

For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.

For the relief of pain associated with equine colic.

### 3.3 Contraindications

See also section 3.7.

Do not use in horses less than 6 weeks of age.

Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.

### 3.4 Special warnings

Treatment of calves with the veterinary medicinal product 20 minutes before dehorning reduces post-operative pain. The veterinary medicinal product alone will not provide adequate pain relief during the dehorning procedure. To obtain adequate pain relief during surgery co-medication with an appropriate analgesic is needed.

### 3.5 Special precautions for use

Special precautions for safe use in the target species:

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in very severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

In case of inadequate relief of pain when used in the treatment of equine colic, careful re-evaluation of the diagnosis should be made as this could indicate the need for surgical intervention.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Accidental self-injection may give rise to pain. People with known hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAID) should avoid contact with the veterinary medicinal product. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment:

Not applicable.

### 3.6 Adverse events

Cattle, pigs and horses:

Common (1 to 10 animals / 100 animals treated):	Injection site swelling <sup>1</sup>
Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Anaphylactoid reaction <sup>2</sup>

<sup>1</sup> Transient swelling following subcutaneous administration in cattle and intravenous administration in horses.

<sup>2</sup> May be serious (including fatal) and should be treated symptomatically.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing



authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### **3.7 Use during pregnancy, lactation or lay**

#### Pregnancy and lactation:

Cattle and pigs: Can be used during pregnancy and lactation.

Horses: Do not use in pregnant or lactating mares.

See also section 3.3.

### **3.8 Interaction with other medicinal products and other forms of interaction**

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.

### **3.9 Administration routes and dosage**

#### Cattle:

Single subcutaneous or intravenous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 2.5 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.

#### Pigs:

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2 ml/100 kg body weight) in combination with antibiotic therapy, as appropriate. If required, a second administration of meloxicam can be given after 24 hours.

#### Horses:

Single intravenous injection at a dosage of 0.6 mg meloxicam/kg body weight (i.e. 3 ml/100 kg body weight).

Avoid introduction of contamination during use.

When treating groups of animals, use a draw-off needle to avoid excessive broaching of the stopper. The maximum number of broachings should be limited to 20.

### **3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

In the case of overdose symptomatic treatment should be initiated.

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

### **3.12 Withdrawal periods**

#### Cattle:

Meat and offal: 15 days.

Milk: 5 days.

#### Pigs:

Meat and offal: 5 days.

#### Horses:

Meat and offal: 5 days.

Not authorised for use in horses producing milk for human consumption.

## **4. PHARMACOLOGICAL INFORMATION**

### **4.1 ATCvet code: QM01AC06**

### **4.2 Pharmacodynamics**

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. Meloxicam also has anti-endotoxic properties because it has been shown to inhibit production of thromboxane B2 induced by *E. coli* endotoxin administration in calves, lactating cows and pigs.

### **4.3 Pharmacokinetics**

#### Absorption:

After a single subcutaneous dose of 0.5 mg meloxicam/kg,  $C_{max}$  values of 2.1 µg/ml and 2.7 µg/ml were reached after 7.7 hours and 4 hours in young cattle and lactating cows, respectively.

After two intramuscular doses of 0.4 mg meloxicam/kg, a  $C_{max}$  value of 1.9 µg/ml was reached after 1 hour in pigs.

#### Distribution:

More than 98% of meloxicam is bound to plasma proteins. The highest meloxicam concentrations are to be found in liver and kidney. Comparatively low concentrations are detectable in skeletal muscle and fat.

#### Metabolism:

Meloxicam is predominantly found in plasma. In cattle, meloxicam is also a major excretion product in milk and bile whereas urine contains only traces of the parent compound. In pigs, bile and urine contain only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive. The metabolism in horses has not been investigated.

#### Elimination:

Meloxicam is eliminated with a half-life of 26 hours and 17.5 hours after subcutaneous injection in young cattle and lactating cows, respectively.

In pigs, after intramuscular administration, the mean plasma biological elimination half-life is approximately 2.5 hours.

In horses, after intravenous injection meloxicam is eliminated with a terminal half-life of 8.5 hours. Approximately 50% of the administered dose is eliminated via urine and the remainder via faeces.

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

## **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 30 months.  
Shelf life after first opening the immediate packaging: 28 days.

## **5.3 Special precautions for storage**

Keep the injection vial in the outer carton in order to protect from light.  
Do not refrigerate or freeze. Protect from frost.

## **5.4 Nature and composition of immediate packaging**

Cardboard box with 1 colourless, type I glass injection vial of 50 ml, 100 ml and 250 ml closed with a bromobutyl rubber stopper and sealed with an aluminium cap.

Not all pack sizes may be marketed.

## **5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

## **6. NAME OF THE MARKETING AUTHORISATION HOLDER**

Dopharma Research B.V.

## **7. MARKETING AUTHORISATION NUMBER(S)**

EU/2/09/098/002  
EU/2/09/098/003  
EU/2/09/098/004

## **8. DATE OF FIRST AUTHORISATION**

Date of first authorisation: 07/07/2009.

## **9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

## **10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database](https://medicines.health.europa.eu/veterinary) (<https://medicines.health.europa.eu/veterinary>).

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Melovem 30 mg/ml solution for injection for cattle and pigs

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

### Active substances:

Meloxicam 30 mg

### Excipients:

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Benzyl alcohol	20 mg
Hydrochloric acid/sodium hydroxide	
Meglumine	
Macrogol 1500	
<i>N</i> -Methyl pyrrolidone	200 mg
Water for injections	

Clear yellow solution.

## 3. CLINICAL INFORMATION

### 3.1 Target species

Cattle and pigs.

### 3.2 Indications for use for each target species

#### Cattle:

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.

For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.

For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.

For the relief of post-operative pain following dehorning in calves.

#### Pigs:

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.

For adjunctive therapy in the treatment of puerperal septicaemia and toxæmia (mastitis-metritisagalactia syndrome) with appropriate antibiotic therapy.

### 3.3 Contraindications

See also section 3.7.

Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.

### 3.4 Special warnings

Treatment of calves with the veterinary medicinal product 20 minutes before dehorning reduces post-operative pain. The veterinary medicinal product alone will not provide adequate pain relief during the dehorning procedure. To obtain adequate pain relief during surgery co-medication with an appropriate analgesic is needed.

### 3.5 Special precautions for use

#### Special precautions for safe use in the target species:

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in very severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Accidental self-injection may give rise to pain. People with known hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAID) should avoid contact with the veterinary medicinal product.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Laboratory studies with the excipient N-methyl pyrrolidone have shown evidence of foetal malformations in rabbits and rats. Women of childbearing age, pregnant women or women suspected of being pregnant should use the veterinary medicinal product with serious caution to avoid accidental self-injection.

#### Special precautions for the protection of the environment:

Not applicable.

### 3.6 Adverse events

Cattle and pigs:

Common (1 to 10 animals / 100 animals treated):	Injection site swelling <sup>1</sup>
Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Anaphylactoid reaction <sup>2</sup>

<sup>1</sup> Transient swelling following subcutaneous administration in cattle.

<sup>2</sup> May be serious (including fatal) and should be treated symptomatically.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### 3.7 Use during pregnancy, lactation or lay

#### Pregnancy, lactation and fertility:

The safety of the veterinary medicinal product has not been established in cattle and pigs during pregnancy and lactation or in animals intended for breeding. Laboratory studies with the excipient N-methyl pyrrolidone have shown evidence of foetal malformations in rabbits and rats. Use only according to the benefit-risk assessment by the responsible veterinarian.

See also section 3.3.

### **3.8 Interaction with other medicinal products and other forms of interaction**

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.

### **3.9 Administration routes and dosage**

#### Cattle:

Single subcutaneous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 2.5 ml/150 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.

#### Pigs:

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2 ml/150 kg body weight) in combination with antibiotic therapy, as appropriate. If required, a second administration of meloxicam can be given after 24 hours.

Avoid introduction of contamination during use.

When treating groups of animals, use a draw-off needle to avoid excessive broaching of the stopper. The maximum number of broachings should be limited to 20.

### **3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

In the case of overdose symptomatic treatment should be initiated.

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

### **3.12 Withdrawal periods**

#### Cattle:

Meat and offal: 15 days.

Milk: 5 days.

#### Pigs:

Meat and offal: 5 days.

## **4. PHARMACOLOGICAL INFORMATION**

### **4.1 ATCvet code: QM01AC06**

### **4.2 Pharmacodynamics**

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. Meloxicam also has anti-endotoxic properties because it has been shown to inhibit production of thromboxane B2 induced by *E. coli* endotoxin administration in calves, lactating cows and pigs.

### **4.3 Pharmacokinetics**

#### Absorption:

After a single subcutaneous dose of 0.5 mg meloxicam/kg,  $C_{max}$  values of 2.1 µg/ml and 2.7 µg/ml were reached after 7.7 hours and 4 hours in young cattle and lactating cows, respectively.

After two intramuscular doses of 0.4 mg meloxicam/kg, a  $C_{max}$  value of 1.9 µg/ml was reached after 1 hour in pigs.

#### Distribution:

More than 98% of meloxicam is bound to plasma proteins. The highest meloxicam concentrations are to be found in liver and kidney. Comparatively low concentrations are detectable in skeletal muscle and fat.

#### Metabolism:

Meloxicam is predominantly found in plasma. In cattle, meloxicam is also a major excretion product in milk and bile whereas urine contains only traces of the parent compound. In pigs, bile and urine contain only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.

#### Elimination:

Meloxicam is eliminated with a half-life of 26 hours and 17.5 hours after subcutaneous injection in young cattle and lactating cows, respectively.

In pigs, after intramuscular administration, the mean plasma biological elimination half-life is approximately 2.5 hours.

Approximately 50% of the administered dose is eliminated via urine and the remainder via faeces.

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

### **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 30 months.

Shelf life after first opening the immediate packaging: 28 days.

### **5.3 Special precautions for storage**

This veterinary medicinal product does not require any special temperature storage conditions.

### **5.4 Nature and composition of immediate packaging**

Cardboard box with 1 colourless, type I glass injection vial of 50 ml, 100 ml and 250 ml closed with a bromobutyl rubber stopper and sealed with an aluminium cap.

Not all pack sizes may be marketed.



**5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

**6. NAME OF THE MARKETING AUTHORISATION HOLDER**

Dopharma Research B.V.

**7. MARKETING AUTHORISATION NUMBER(S)**

EU/2/09/098/005

EU/2/09/098/006

EU/2/09/098/007

**8. DATE OF FIRST AUTHORISATION**

Date of first authorisation: 07/07/2009.

**9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

**10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Melovem 15 mg/ml oral suspension for horses

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

### Active substances:

Meloxicam 15 mg

### Excipients:

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Sodium benzoate	1.5 mg
Sorbitol	
Glycerol	
Saccharin sodium	
Xylitol	
Silica, colloidal anhydrous	
Hydroxyethylcellulose	
Citric acid	
Honey aroma	
Water purified	

Yellow, aqueous suspension.

## 3. CLINICAL INFORMATION

### 3.1 Target species

Horses.

### 3.2 Indications for use for each target species

Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses.

### 3.3 Contraindications

Do not use in pregnant or lactating mares.

Do not use in horses suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.

Do not use in horses less than 6 weeks of age.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

### 3.4 Special warnings

None.

### 3.5 Special precautions for use

#### Special precautions for safe use in the target species:

Avoid use in any dehydrated, hypovolaemic or hypotensive animals as there is a potential risk of renal toxicity.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

This product can cause eye irritation. In case of contact with the eyes, immediately rinse thoroughly with water.

#### Special precautions for the protection of the environment:

Not applicable.

### 3.6 Adverse events

Horses:

Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Diarrhoea <sup>1</sup> , appetite loss, lethargy, abdominal pain, colitis, urticaria Anaphylactoid reactions <sup>2</sup>
---	---

<sup>1</sup> Reversible

<sup>2</sup> May be serious (including fatal) and should be treated symptomatically.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### 3.7 Use during pregnancy, lactation or lay

#### Pregnancy and lactation:

Laboratory studies in cattle have not produced any evidence for teratogenic, foetotoxic, or maternotoxic effects. However, no data have been generated in horses. Therefore, the use in this species is not recommended during pregnancy and lactation.

### 3.8 Interaction with other medicinal products and other forms of interaction

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.

### **3.9 Administration routes and dosage**

To be administered either mixed with food or directly into the mouth at a dosage of 0.6 mg meloxicam/kg body weight (i.e. 4 ml/100 kg body weight), once daily, up to 14 days.

In case the product is mixed with food, it should be added to a small quantity of food, prior to feeding.

The suspension should be given using the measuring syringe provided in the package. The syringe has a kg-body weight scale.

Shake well before use.

After administration of the veterinary medicinal product, close the bottle by replacing the cap, wash the measuring syringe with warm water and let it dry.

Avoid introduction of contamination during use.

### **3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

In the case of overdose symptomatic treatment should be initiated.

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

### **3.12 Withdrawal periods**

Meat and offal: 3 days.

Not authorised for use in animals producing milk for human consumption.

## **4. PHARMACOLOGICAL INFORMATION**

### **4.1 ATCvet code: QM01AC06**

### **4.2 Pharmacodynamics**

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. Meloxicam also has anti-endotoxic properties because it has been shown to inhibit production of thromboxane B2 induced by *E. coli* endotoxin administration in calves and pigs.

### **4.3 Pharmacokinetics**

#### Absorption:

When the product is used according to the recommended dosage regime the oral bioavailability is approximately 98%. Maximal plasma concentrations are obtained after approximately 2–3 hours. The accumulation factor of 1.08 suggests that meloxicam does not accumulate when administered daily.

#### Distribution:

Approximately 98% of meloxicam is bound to plasma proteins. The volume of distribution is 0.12 l/kg.

### Metabolism:

The metabolism is qualitatively similar in rats, mini-pigs, humans, cattle and pigs although quantitatively there are differences. The major metabolites found in all species were the 5-hydroxy- and 5-carboxy- metabolites and the oxalyl-metabolite. The metabolism in horses has not been investigated. All major metabolites have been shown to be pharmacologically inactive.

### Elimination:

Meloxicam is eliminated with a terminal half-life of 7.7 hours.

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

None known.

### **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

Shelf life after first opening the immediate packaging: 6 months.

### **5.3 Special precautions for storage**

This veterinary medicinal product does not require any special storage conditions.

After first opening, store below 25 °C.

### **5.4 Nature and composition of immediate packaging**

White, rectangular high density polyethylene bottles of 250 ml or 500 ml of product with a narrow mouth opening, closed with a white polypropylene screw cap, and provided with a polypropylene transparent lid with space to include a polypropylene measuring syringe with a synthetic rubber piston. Cardboard box with 1 white, round high-density polyethylene bottle of 100 ml of product closed with a white polypropylene screw cap and 1 polypropylene measuring syringe with a synthetic rubber piston.

Not all pack sizes may be marketed.

### **5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

## **6. NAME OF THE MARKETING AUTHORISATION HOLDER**

Dopharma Research B.V.

## **7. MARKETING AUTHORISATION NUMBER(S)**

EU/2/09/098/008

EU/2/09/098/009  
EU/2/09/098/010

**8. DATE OF FIRST AUTHORISATION**

Date of first authorisation: 07/07/2009.

**9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

**10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

## **ANNEX II**

### **OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

None.

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**



## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**Cardboard box**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Melovem 5 mg/ml solution for injection

**2. STATEMENT OF ACTIVE SUBSTANCES**

Meloxicam 5 mg/ml

**3. PACKAGE SIZE**

100 ml

**4. TARGET SPECIES**

Cattle (calves and young cattle) and pigs

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Cattle: **s.c.**  
Pigs: **i.m.**

**7. WITHDRAWAL PERIODS**

Withdrawal periods:  
Cattle: Meat and offal: 15 days.  
Not authorised for use in animals producing milk for human consumption.  
Pigs: Meat and offal: 5 days.

**8. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached use within 28 days.  
Once broached use by...

**9. SPECIAL STORAGE PRECAUTIONS**

Keep the injection vial in the outer carton in order to protect from light.

**10. THE WORDS "READ THE PACKAGE LEAFLET BEFORE USE"**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

Dopharma Research B.V.

**14. MARKETING AUTHORISATION NUMBERS**

EU/2/09/098/001

**15. BATCH NUMBER**

Lot {number}

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

**Glass vial**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Melovem 5 mg/ml solution for injection

**2. STATEMENT OF ACTIVE SUBSTANCES**

Meloxicam 5 mg/ml

**3. TARGET SPECIES**

Cattle (calves and young cattle) and pigs

**4. ROUTES OF ADMINISTRATION**

Cattle: **s.c.**  
Pigs: **i.m.**  
Read the package leaflet before use.

**5. WITHDRAWAL PERIODS**

Withdrawal periods:  
Cattle: Meat and offal: 15 days.  
Not authorised for use in animals producing milk for human consumption.  
Pigs: Meat and offal: 5 days.

**6. EXPIRY DATE**

Exp. {mm/yyyy}  
Once broached use within 28 days.  
Once broached use by...

**7. SPECIAL STORAGE PRECAUTIONS**

Keep the injection vial in the outer carton in order to protect from light.

**8. NAME OF THE MARKETING AUTHORISATION HOLDER**

Dopharma Research B.V.

**9. BATCH NUMBER**

Lot {number}

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**Cardboard box**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Melovem 20 mg/ml solution for injection

**2. STATEMENT OF ACTIVE SUBSTANCES**

Meloxicam 20 mg/ml

**3. PACKAGE SIZE**

50 ml  
100 ml  
250 ml

**4. TARGET SPECIES**

Cattle, pigs and horses

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Cattle: **s.c.** or **i.v.**  
Pigs: **i.m.**  
Horses: **i.v.**

**7. WITHDRAWAL PERIODS**

Withdrawal periods:  
Cattle: Meat and offal: 15 days; Milk: 5 days.  
Pigs, horses: Meat and offal: 5 days.  
Not authorised for use in horses producing milk for human consumption.

**8. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached use within 28 days.  
Once broached use by...

**9. SPECIAL STORAGE PRECAUTIONS**

Keep the vial in the outer carton in order to protect from light.  
Do not refrigerate or freeze. Protect from frost.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

Dopharma Research B.V.

**14. MARKETING AUTHORISATION NUMBERS**

EU/2/09/098/002 (50 ml)  
EU/2/09/098/003 (100 ml)  
EU/2/09/098/004 (250 ml)

**15. BATCH NUMBER**

Lot {number}

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

**Glass vial 100 ml and 250 ml**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Melovem 20 mg/ml solution for injection

**2. STATEMENT OF ACTIVE SUBSTANCES**

Meloxicam 20 mg/ml

**3. TARGET SPECIES**

Cattle, pigs and horses

**4. ROUTES OF ADMINISTRATION**

Cattle: **s.c.** or **i.v.**

Pigs: **i.m.**

Horses: **i.v.**

Read the package leaflet before use.

**5. WITHDRAWAL PERIODS**

Withdrawal periods:

Cattle: Meat and offal: 15 days; Milk: 5 days.

Pigs, horses: Meat and offal: 5 days.

Not authorised for use in horses producing milk for human consumption.

**6. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached use within 28 days.

Once broached use by...

**7. SPECIAL STORAGE PRECAUTIONS**

Keep the vial in the outer carton in order to protect from light.

Do not refrigerate or freeze. Protect from frost.

**8. NAME OF THE MARKETING AUTHORISATION HOLDER**

Dopharma Research B.V.



**9. BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**Glass vial 50 ml**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Melovem 20 mg/ml for cattle, pigs and horses

**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

Meloxicam 20 mg/ml

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached use within 28 days.

Once broached use by...

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**Cardboard box**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Melovem 30 mg/ml solution for injection

**2. STATEMENT OF ACTIVE SUBSTANCES**

Meloxicam 30 mg/ml

**3. PACKAGE SIZE**

50 ml  
100 ml  
250 ml

**4. TARGET SPECIES**

Cattle and pigs

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Cattle: **s.c.**  
Pigs: **i.m.**

**7. WITHDRAWAL PERIODS**

Withdrawal periods:  
Cattle: Meat and offal: 15 days; Milk: 5 days.  
Pigs: Meat and offal: 5 days.

**8. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached use within 28 days.  
Once broached use by...

**9. SPECIAL STORAGE PRECAUTIONS**

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

Dopharma Research B.V.

**14. MARKETING AUTHORISATION NUMBERS**

EU/2/09/098/005 (50 ml)

EU/2/09/098/006 (100 ml)

EU/2/09/098/007 (250 ml)

**15. BATCH NUMBER**

Lot {number}

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

**Glass vial 100 ml and 250 ml**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Melovem 30 mg/ml solution for injection

**2. STATEMENT OF ACTIVE SUBSTANCES**

Meloxicam 30 mg/ml

**3. TARGET SPECIES**

Cattle and pigs

**4. ROUTES OF ADMINISTRATION**

Cattle: **s.c.**  
Pigs: **i.m.**  
Read the package leaflet before use.

**5. WITHDRAWAL PERIODS**

Withdrawal periods:  
Cattle: Meat and offal: 15 days; Milk: 5 days.  
Pigs: Meat and offal: 5 days.

**6. EXPIRY DATE**

Exp. {mm/yyyy}  
  
Once broached use within 28 days.  
Once broached use by...

**7. SPECIAL STORAGE PRECAUTIONS**

**8. NAME OF THE MARKETING AUTHORISATION HOLDER**

Dopharma Research B.V.

**9. BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**Glass vial 50 ml**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Melovem 30 mg/ml for cattle and pigs

**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

Meloxicam 30 mg/ml

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached use within 28 days

Once broached use by...

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**Cardboard box 100 ml**  
**HDPE bottle 250 ml and 500 ml**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Melovem 15 mg/ml oral suspension

**2. STATEMENT OF ACTIVE SUBSTANCES**

Meloxicam 15 mg/ml

**3. PACKAGE SIZE**

100 ml  
250 ml  
500 ml

**4. TARGET SPECIES**

Horses

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Oral use.  
To be administered either mixed with food or directly into the mouth.

**7. WITHDRAWAL PERIODS**

Withdrawal periods:  
Meat and offal: 3 days.  
Not authorised for use in animals producing milk for human consumption.

**8. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached use within 6 months.  
Once broached use by...

**9. SPECIAL STORAGE PRECAUTIONS**

After first opening, store below 25 °C.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

Dopharma Research B.V.

**14. MARKETING AUTHORISATION NUMBERS**

EU/2/09/098/008 (100 ml)

EU/2/09/098/009 (250 ml)

EU/2/09/098/010 (500 ml)

**15. BATCH NUMBER**

Lot {number}



**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

**HDPE bottle**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Melovem 15 mg/ml oral suspension

**2. STATEMENT OF ACTIVE SUBSTANCES**

Meloxicam 15 mg/ml

**3. TARGET SPECIES**

Horses

**4. ROUTES OF ADMINISTRATION**

Oral use.

To be administered either mixed with food or directly into the mouth.

Read the package leaflet before use.

**5. WITHDRAWAL PERIODS**

Withdrawal periods:

Meat and offal: 3 days.

Not authorised for use in animals producing milk for human consumption.

**6. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached use within 6 months.

Once broached use by...

**7. SPECIAL STORAGE PRECAUTIONS**

After first opening, store below 25 °C.

**8. NAME OF THE MARKETING AUTHORISATION HOLDER**

Dopharma Research B.V.

**9. BATCH NUMBER**

Lot {number}

## **B. PACKAGE LEAFLET**

## PACKAGE LEAFLET

### **1. Name of the veterinary medicinal product**

Melovem 5 mg/ml solution for injection for cattle and pigs

### **2. Composition**

Each ml contains:

**Active substances:**

Meloxicam 5 mg

**Excipients:**

Benzyl alcohol 50 mg

Clear, greenish yellow solution.

### **3. Target species**

Cattle (calves and young cattle) and pigs.

### **4. Indications for use**

**Cattle:**

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.

For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.

For the relief of post-operative pain following dehorning in calves.

**Pigs:**

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.

For the relief of post-operative pain associated with minor soft tissue surgery such as castration.

### **5. Contraindications**

Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.

Do not use in pigs less than 2 days old.

### **6. Special warnings**

Special warnings:

Treatment of calves with the veterinary medicinal product 20 minutes before dehorning reduces post-operative pain. The veterinary medicinal product alone will not provide adequate pain relief during the dehorning procedure. To obtain adequate pain relief during surgery co-medication with an appropriate analgesic is needed.

Treatment of piglets with the veterinary medicinal product before castration reduces post-operative pain. To obtain pain relief during surgery co-medication with an appropriate anaesthetic/sedative is needed.

To obtain the best possible pain relieving effect post-surgery the veterinary medicinal product should be administered 30 minutes before surgical intervention.

Special precautions for safe use in the target species:

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in very severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Accidental self-injection may give rise to pain. People with known hypersensitivity to Non-Steroidal AntiInflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product. In case of accidental self-injection, seek medical advice immediately and show this package leaflet or the label to the physician.

Pregnancy and lactation:

Cattle: Can be used during pregnancy.

Pigs: Can be used during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.

Overdose:

In the case of overdosage, symptomatic treatment should be initiated.

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

## **7. Adverse events**

Cattle and pigs:

Common (1 to 10 animals / 100 animals treated):	Injection site pain <sup>1</sup> , Injection site swelling <sup>1</sup>
Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Anaphylactoid reaction <sup>2</sup>

<sup>1</sup> Transient.

<sup>2</sup> May be serious (including fatal) and should be treated symptomatically.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or its local representative using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

## **8. Dosage for each species, routes and method of administration**

**Cattle:**

Single subcutaneous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 10 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.

**Pigs:**

Locomotor disorders:

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2 ml/25 kg body weight).

If required, a second administration of meloxicam can be given after 24 hours. It is recommended to administer the second injection at a different site since local tolerance has been assessed after single injection only.

Reduction of post-operative pain:

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 0.4 ml/5 kg body weight) before surgery.

Particular care should be taken with regard to the accuracy of dosing including the use of an appropriate dosing device and careful estimation of body weight.

**9. Advice on correct administration**

Avoid introduction of contamination during use.

**10. Withdrawal periods**

Cattle: Meat and offal: 15 days.

Not authorised for use in animals producing milk for human consumption.

Pigs: Meat and offal: 5 days.

**11. Special storage precautions**

Keep out of the sight and reach of children.

Keep the injection vial in the outer carton in order to protect from light.

This veterinary medicinal product does not require any special temperature storage conditions.

Shelf life after first opening the immediate packaging: 28 days.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and bottle after Exp. The expiry date refers to the last day of that month.

**12. Special precautions for disposal**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

**13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

**14. Marketing authorisation numbers and pack sizes**

EU/2/09/098/001

Cardboard box with 1 vial of 100 ml.

**15. Date on which the package leaflet was last revised**

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

**16. Contact details**

Marketing authorisation holder and contact details to report suspected adverse events:

Dopharma Research B.V.  
Zalmweg 24  
NL-4941 VX Raamsdonksveer  
Tel: +31-162-582000  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

Manufacturer responsible for batch release:

Dopharma B.V.  
Zalmweg 24  
NL-4941 VX Raamsdonksveer

Local representative and contact details to report suspected adverse events:

**België/Belgique/Belgien**

Dopharma Research B.V.  
Zalmweg 24  
NL-4941 VX Raamsdonksveer  
Nederland/Pays-Bas  
Tel: +32 475 367 776  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

**Lietuva**

Dopharma Polska  
ul. Wojskowa 6/B02  
60 792 Poznań  
Lenkija  
Tel.: +48 516 052 508  
[PhV@dopharma.pl](mailto:PhV@dopharma.pl)

**Република България**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
Нидерландия  
Tel. +31-162-582000  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

**Luxembourg/Luxemburg**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
Pays-Bas  
Tel: +32 475 367 776  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

**Česká republika**

Cymedica, spol. s r.o.  
Pod Nádražím 308/24  
CZ 268 01 Hořovice  
Tel: +420 311 706 211  
[farmakovigilance@cymedica.com](mailto:farmakovigilance@cymedica.com)

**Danmark**

Salfarm Danmark A/S  
Nordager 19  
DK- 6000 Kolding  
Tlf: +45 7550 8080  
[info@salfarm.com](mailto:info@salfarm.com)

**Deutschland**

Dopharma Deutschland GmbH  
Hansestr. 53  
DE-48165 Münster  
Tel: +49 (0)2501 594 349 20  
[pharmakovigilanz@dopharma.de](mailto:pharmakovigilanz@dopharma.de)

**Eesti**

Dopharma Polska  
ul. Wojskowa 6/B02  
60 792 Poznań  
Poola  
Tel.: +48 516 052 508  
[PhV@dopharma.pl](mailto:PhV@dopharma.pl)

**Ελλάδα**

Neocell ΕΠΕ  
10ο χλμ. Εθνικής Οδού Αθηνών-Λαμίας  
EL-14451 Μεταμόρφωση Αττικής  
Τηλ: +30 210 2844333  
[pharmacovigilance@neocell.gr](mailto:pharmacovigilance@neocell.gr)

**España**

Dopharma Iberia  
Avenida de la Llana 123  
ES-08191, Rubí – Barcelona  
Tel: +34 637 370492  
[farmacovigilancia@dopharma-iberia.com](mailto:farmacovigilancia@dopharma-iberia.com)

**Magyarország**

Dopharma Vet S.R.L.  
Str. Aeroport nr. 44  
Localitatea Ghiroda  
Județul Timiș 307200  
România  
Tel: +40 728 138 903  
[a.ardelean@dopharma.ro](mailto:a.ardelean@dopharma.ro)

**Malta**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
L-Olanda  
Tel. +31-162-582000  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

**Nederland**

Dopharma Research B.V.  
Zalmweg 24  
NL-4941 VX Raamsdonksveer  
Tel. +31-162-582000  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

**Norge**

Salfarm Scandinavia AS  
Fridtjof Nansens Plass 4  
N-0160 Oslo  
Tlf: +47 902 97 102  
[norge@salfarm.com](mailto:norge@salfarm.com)

**Österreich**

Dopharma Deutschland GmbH  
Hansestr. 53  
48165 Münster  
Deutschland  
Tel: +49 (0)2501 594 349 20  
[pharmakovigilanz@dopharma.de](mailto:pharmakovigilanz@dopharma.de)

**Polska**

Dopharma Polska  
ul. Wojskowa 6/B02  
PL – 60 792 Poznań  
Tel.: +48 516 052 508  
[PhV@dopharma.pl](mailto:PhV@dopharma.pl)



**France**

Laboratoire LCV  
Z.I. Plessis Beucher  
FR-35220 Châteaubourg  
Tél: +33 2 99 00 92 92

**Hrvatska**

Arnika Veterina d.o.o.  
Vidikovac 20  
HR-10000 Zagreb  
Tel +385 91 364 3731  
[visnja.pintar-alicevic@arnika-veterina.hr](mailto:visnja.pintar-alicevic@arnika-veterina.hr)

**Ireland**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
The Netherlands  
Tel. +31-162-582000  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

**Ísland**

Salfarm Danmark A/S  
Nordager 19  
6000 Kolding  
Danmörk  
Tlf: +45 75 50 80 80  
[info@salfarm.com](mailto:info@salfarm.com)

**Italia**

Dopharma Italia S.R.L.  
Via delle Porte Nuove, 20  
IT-50144 Firenze  
Tel +39 (346) 14 26 164  
[servizioclienti@dopharma.it](mailto:servizioclienti@dopharma.it)

**Κόπος**

Neocell ΕΠΕ  
10ο χλμ. Εθνικής Οδού Αθηνών-Λαμίας  
14451 Μεταμόρφωση Αττικής  
Ελλάδα  
Τηλ: +30 210 2844333  
[pharmacovigilance@neocell.gr](mailto:pharmacovigilance@neocell.gr)

**Portugal**

VETLIMA-Sociedade Distribuidora de Produtos  
Agro-Pecuários, S.A.  
Centro Empresarial da Rainha, Lote 27  
PT-2050-501 Vila Nova da Rainha  
Tel: +351 263 406 570

Detalhes de contacto para comunicar suspeitas  
de eventos adversos:

[farmacovigilancia@vetlima.com](mailto:farmacovigilancia@vetlima.com)

Tel: +351 964404163

**România**

Dopharma Vet S.R.L.  
Str. Aeroport nr. 44  
Localitatea Ghiroda  
RO-Județul Timiș 307200  
Tel: +40 728 138 903  
[a.ardelean@dopharma.ro](mailto:a.ardelean@dopharma.ro)

**Slovenija**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
Nizozemska  
Tel. +31-162-582000  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

**Slovenská republika**

Cymedica, spol. s r.o.  
Pod Nádražím 308/24  
268 01 Hořovice  
Česká republika  
Tel: +420 311 706 211  
[farmakovigilance@cymedica.com](mailto:farmakovigilance@cymedica.com)

**Suomi/Finland**

FaunaPharma Oy  
c/o Oriola Finland Oy  
PL 8  
FI-02101 ESPOO  
Puh: +358 10 375 3050  
[info@faunapharma.fi](mailto:info@faunapharma.fi)

**Sverige**

Salfarm Scandinavia AB  
Florettgatan 29C  
2. Vån  
SE-254 67 Helsingborg  
Tel: +46 (0)767 834 810  
[scan@salfarm.com](mailto:scan@salfarm.com)

**Latvija**

Dopharma Polska  
ul. Wojskowa 6/B02  
60 792 Poznań  
Polija  
Tel.: +48 516 052 508  
[PhV@dopharma.pl](mailto:PhV@dopharma.pl)

**United Kingdom (Northern Ireland)**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
The Netherlands  
Tel. +31-162-582000  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

## PACKAGE LEAFLET

### 1. Name of the veterinary medicinal product

Melovem 20 mg/ml solution for injection for cattle, pigs and horses

### 2. Composition

Each ml contains:

#### Active substances:

Meloxicam 20 mg

#### Excipients:

Ethanol 150 mg

Clear yellow solution.

### 3. Target species

Cattle, pigs and horses.

### 4. Indications for use

#### Cattle:

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.

For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.

For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.

For the relief of post-operative pain following dehorning in calves.

#### Pigs:

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.

For adjunctive therapy in the treatment of puerperal septicaemia and toxemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.

#### Horses:

For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.

For the relief of pain associated with equine colic.

### 5. Contraindications

Do not use in horses less than 6 weeks of age.

Do not use in pregnant or lactating mares.

Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.

### 6. Special warnings

Special warnings:

Treatment of calves with the veterinary medicinal product 20 minutes before dehorning reduces post-operative pain. The veterinary medicinal product alone will not provide adequate pain relief during the dehorning procedure. To obtain adequate pain relief during surgery co-medication with an appropriate analgesic is needed.

Special precautions for safe use in the target species:

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in very severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

In case of inadequate relief of pain when used in the treatment of equine colic, careful re-evaluation of the diagnosis should be made as this could indicate the need for surgical intervention.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Accidental self-injection may give rise to pain. People with known hypersensitivity to Non-Steroidal AntiInflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product. In case of accidental self-injection, seek medical advice immediately and show this package leaflet or the label to the physician.

Pregnancy and lactation:

Cattle and pigs: Can be used during pregnancy and lactation.

Horses: Do not use in pregnant or lactating mares.

Interaction with other medicinal products and other forms of interaction:

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.

Overdose:

In the case of overdose, symptomatic treatment should be initiated.

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

**7. Adverse events**

Cattle, pigs and horses:

Common (1 to 10 animals / 100 animals treated):	Injection site swelling <sup>1</sup>
Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Anaphylactoid reaction <sup>2</sup>

<sup>1</sup> Transient swelling following subcutaneous administration in cattle and intravenous administration in horses.

<sup>2</sup> May be serious (including fatal) and should be treated symptomatically.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or its local representative using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

## **8. Dosage for each species, routes and method of administration**

### **Cattle:**

Single subcutaneous or intravenous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 2.5 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.

### **Pigs:**

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2 ml/100 kg body weight) in combination with antibiotic therapy, as appropriate. If required, a second administration of meloxicam can be given after 24 hours.

### **Horses:**

Single intravenous injection at a dosage of 0.6 mg meloxicam/kg body weight (i.e. 3 ml/100 kg body weight).

## **9. Advice on correct administration**

Avoid introduction of contamination during use.

When treating groups of animals, use a draw-off needle to avoid excessive broaching of the stopper. The maximum number of broachings should be limited to 20.

## **10. Withdrawal periods**

### **Cattle:**

Meat and offal: 15 days.

Milk: 5 days.

### **Pigs:**

Meat and offal: 5 days.

### **Horses:**

Meat and offal: 5 days.

Not authorised for use in animals producing milk for human consumption.

## **11. Special storage precautions**

Keep out of the sight and reach of children.

Keep the injection vial in the outer carton in order to protect from light.

Do not refrigerate or freeze. Protect from frost.

Shelf life after first opening the immediate packaging: 28 days.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and bottle after Exp. The expiry date refers to the last day of that month.

## **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

**13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

**14. Marketing authorisation numbers and pack sizes**

EU/2/09/098/002

EU/2/09/098/003

EU/2/09/098/004

Cardboard box with 1 vial of 50 ml, 100 ml or 250 ml.

Not all pack sizes may be marketed.

**15. Date on which the package leaflet was last revised**

Detailed information on this veterinary medicinal product is available in the [Union Product Database](https://medicines.health.europa.eu/veterinary) (<https://medicines.health.europa.eu/veterinary>).

**16. Contact details**

Marketing authorisation holder and contact details to report suspected adverse events:

Dopharma Research B.V.  
Zalmweg 24  
NL-4941 VX Raamsdonksveer  
Tel: +31-162-582000  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

Manufacturer responsible for batch release:

Dopharma B.V.  
Zalmweg 24  
NL-4941 VX Raamsdonksveer

Local representative and contact details to report suspected adverse events:

**België/Belgique/Belgien**

Dopharma Research B.V.  
Zalmweg 24  
NL-4941 VX Raamsdonksveer  
Nederland/Pays-Bas  
Tel: +32 475 367 776  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

**Lietuva**

Dopharma Polska  
ul. Wojskowa 6/B02  
60 792 Poznań  
Lenkija  
Tel.: +48 516 052 508  
[PhV@dopharma.pl](mailto:PhV@dopharma.pl)

**Република България**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
Нидерландия  
Tel. +31-162-582000  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

**Česká republika**

Cymedica, spol. s r.o.  
Pod Nádražím 308/24  
CZ 268 01 Hořovice  
Tel: +420 311 706 211  
[farmakovigilance@cymedica.com](mailto:farmakovigilance@cymedica.com)

**Danmark**

Salfarm Danmark A/S  
Nordager 19  
DK- 6000 Kolding  
Tlf: +45 7550 8080  
[info@salfarm.com](mailto:info@salfarm.com)

**Deutschland**

Dopharma Deutschland GmbH  
Hansestr. 53  
DE-48165 Münster  
Tel: +49 (0)2501 594 349 20  
[pharmakovigilanz@dopharma.de](mailto:pharmakovigilanz@dopharma.de)

**Eesti**

Dopharma Polska  
ul. Wojskowa 6/B02  
60 792 Poznań  
Poola  
Tel.: +48 516 052 508  
[PhV@dopharma.pl](mailto:PhV@dopharma.pl)

**Ελλάδα**

Neocell ΕΠΕ  
10ο χλμ. Εθνικής Οδού Αθηνών-Λαμίας  
EL-14451 Μεταμόρφωση Αττικής  
Τηλ: +30 210 2844333  
[pharmacovigilance@neocell.gr](mailto:pharmacovigilance@neocell.gr)

**España**

Dopharma Iberia  
Avenida de la Llana 123  
ES-08191, Rubí – Barcelona  
Tel: +34 637 370492  
[farmacovigilancia@dopharma-iberia.com](mailto:farmacovigilancia@dopharma-iberia.com)

**Luxembourg/Luxemburg**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
Pays-Bas  
Tel: +32 475 367 776  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

**Magyarország**

Dopharma Vet S.R.L.  
Str. Aeroport nr. 44  
Localitatea Ghiroda  
Județul Timiș 307200  
România  
Tel: +40 728 138 903  
[a.ardelean@dopharma.ro](mailto:a.ardelean@dopharma.ro)

**Malta**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
L-Olanda  
Tel. +31-162-582000  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

**Nederland**

Dopharma Research B.V.  
Zalmweg 24  
NL-4941 VX Raamsdonksveer  
Tel. +31-162-582000  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

**Norge**

Salfarm Scandinavia AS  
Fridtjof Nansens Plass 4  
N-0160 Oslo  
Tlf: +47 902 97 102  
[norge@salfarm.com](mailto:norge@salfarm.com)

**Österreich**

Dopharma Deutschland GmbH  
Hansestr. 53  
48165 Münster  
Deutschland  
Tel: +49 (0)2501 594 349 20  
[pharmakovigilanz@dopharma.de](mailto:pharmakovigilanz@dopharma.de)

**Polska**

Dopharma Polska  
ul. Wojskowa 6/B02  
PL – 60 792 Poznań  
Tel.: +48 516 052 508  
[PhV@dopharma.pl](mailto:PhV@dopharma.pl)

**France**

Laboratoire LCV  
Z.I. Plessis Beucher  
FR-35220 Châteaubourg  
Tél: +33 2 99 00 92 92

**Hrvatska**

Arnika Veterina d.o.o.  
Vidikovac 20  
HR-10000 Zagreb  
Tel +385 91 364 3731  
[visnja.pintar-alicevic@arnika-veterina.hr](mailto:visnja.pintar-alicevic@arnika-veterina.hr)

**Ireland**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
The Netherlands  
Tel. +31-162-582000  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

**Ísland**

Salfarm Danmark A/S  
Nordager 19  
6000 Kolding  
Danmörk  
Tlf: +45 75 50 80 80  
[info@salfarm.com](mailto:info@salfarm.com)

**Italia**

Dopharma Italia S.R.L.  
Via delle Porte Nuove, 20  
IT-50144 Firenze  
Tel +39 (346) 14 26 164  
[servizioclienti@dopharma.it](mailto:servizioclienti@dopharma.it)

**Κύπρος**

Neocell ΕΠΕ  
10ο χλμ. Εθνικής Οδού Αθηνών-Λαμίας  
14451 Μεταμόρφωση Αττικής  
Ελλάδα  
Τηλ: +30 210 2844333  
[pharmacovigilance@neocell.gr](mailto:pharmacovigilance@neocell.gr)

**Portugal**

VETLIMA-Sociedade Distribuidora de Produtos  
Agro-Pecuários, S.A.  
Centro Empresarial da Rainha, Lote 27  
PT-2050-501 Vila Nova da Rainha  
Tel: +351 263 406 570

Detalhes de contacto para comunicar suspeitas  
de eventos adversos:

[farmacovigilancia@vetlima.com](mailto:farmacovigilancia@vetlima.com)

Tel: +351 964404163

**România**

Dopharma Vet S.R.L.  
Str. Aeroport nr. 44  
Localitatea Ghiroda  
RO-Județul Timiș 307200  
Tel: +40 728 138 903  
[a.ardelean@dopharma.ro](mailto:a.ardelean@dopharma.ro)

**Slovenija**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
Nizozemska  
Tel. +31-162-582000  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

**Slovenská republika**

Cymedica, spol. s r.o.  
Pod Nádražím 308/24  
268 01 Hořovice  
Česká republika  
Tel: +420 311 706 211  
[farmakovigilance@cymedica.com](mailto:farmakovigilance@cymedica.com)

**Suomi/Finland**

FaunaPharma Oy  
c/o Oriola Finland Oy  
PL 8  
FI-02101 ESPOO  
Puh: +358 10 375 3050  
[info@faunapharma.fi](mailto:info@faunapharma.fi)

**Sverige**

Salfarm Scandinavia AB  
Florettgatan 29C  
2. Vån  
SE-254 67 Helsingborg  
Tel: +46 (0)767 834 810  
[scan@salfarm.com](mailto:scan@salfarm.com)



**Latvija**

Dopharma Polska  
ul. Wojskowa 6/B02  
60 792 Poznań  
Polija  
Tel.: +48 516 052 508  
[PhV@dopharma.pl](mailto:PhV@dopharma.pl)

**United Kingdom (Northern Ireland)**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
The Netherlands  
Tel. +31-162-582000  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

## PACKAGE LEAFLET

### 1. Name of the veterinary medicinal product

Melovem 30 mg/ml solution for injection for cattle and pigs

### 2. Composition

Each ml contains:

#### Active substances:

Meloxicam 30 mg

#### Excipients:

Benzyl alcohol 20 mg

N-Methyl pyrrolidone 200 mg

Clear yellow solution.

### 3. Target species

Cattle and pigs.

### 4. Indications for use

#### Cattle:

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.

For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.

For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.

For the relief of post-operative pain following dehorning in calves.

#### Pigs:

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.

For adjunctive therapy in the treatment of puerperal septicaemia and toxæmia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.

### 5. Contraindications

Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.

### 6. Special warnings

#### Special warnings:

Treatment of calves with the veterinary medicinal product 20 minutes before dehorning reduces post-operative pain. The veterinary medicinal product alone will not provide adequate pain relief during the

dehorning procedure. To obtain adequate pain relief during surgery co-medication with an appropriate analgesic is needed.

Special precautions for safe use in the target species:

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in very severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Accidental self-injection may give rise to pain. People with known hypersensitivity to Non-Steroidal AntiInflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product. In case of accidental self-injection, seek medical advice immediately and show this package leaflet or the label to the physician. Laboratory studies with the excipient N-methyl pyrrolidone have shown evidence of foetal malformations in rabbits and rats. Women of childbearing age, pregnant women or women suspected of being pregnant should use the veterinary medicinal product with serious caution to avoid accidental self-injection.

Pregnancy, lactation and fertility:

The safety of the veterinary medicinal product has not been established in cattle and pigs during pregnancy and lactation or in animals intended for breeding. Laboratory studies with the excipient N-methyl pyrrolidone have shown evidence of foetal malformations in rabbits and rats. Use only according to the benefit-risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.

Overdose:

In the case of overdose, symptomatic treatment should be initiated.

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

## **7. Adverse events**

Cattle and pigs:

Common (1 to 10 animals / 100 animals treated):	Injection site swelling <sup>1</sup>
Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Anaphylactoid reaction <sup>2</sup>

<sup>1</sup> Transient swelling following subcutaneous administration in cattle.

<sup>2</sup> May be serious (including fatal) and should be treated symptomatically.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or its local representative using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

## **8. Dosage for each species, routes and method of administration**

**Cattle:**

Single subcutaneous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 2.5 ml/150 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.

**Pigs:**

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2 ml/150 kg body weight) in combination with antibiotic therapy, as appropriate. If required, a second administration of meloxicam can be given after 24 hours.

**9. Advice on correct administration**

Avoid introduction of contamination during use.

When treating groups of animals, use a draw-off needle to avoid excessive broaching of the stopper. The maximum number of broachings should be limited to 20.

**10. Withdrawal periods****Cattle:**

Meat and offal: 15 days.

Milk: 5 days.

**Pigs:**

Meat and offal: 5 days.

**11. Special storage precautions**

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special temperature storage conditions.

Shelf life after first opening the immediate packaging: 28 days.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and bottle after Exp. The expiry date refers to the last day of that month.

**12. Special precautions for disposal**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

**13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

**14. Marketing authorisation numbers and pack sizes**

EU/2/09/098/005

EU/2/09/098/006  
EU/2/09/098/007

Cardboard box with 1 vial of 50 ml, 100 ml or 250 ml.

Not all pack sizes may be marketed.

#### **15. Date on which the package leaflet was last revised**

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

#### **16. Contact details**

Marketing authorisation holder and contact details to report suspected adverse events:

Dopharma Research B.V.  
Zalmweg 24  
NL-4941 VX Raamsdonksveer  
Tel: +31-162-582000  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

Manufacturer responsible for batch release:

Dopharma B.V.  
Zalmweg 24  
NL-4941 VX Raamsdonksveer

Local representative and contact details to report suspected adverse events:

##### **België/Belgique/Belgien**

Dopharma Research B.V.  
Zalmweg 24  
NL-4941 VX Raamsdonksveer  
Nederland/Pays-Bas  
Tel: +32 475 367 776  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

##### **Lietuva**

Dopharma Polska  
ul. Wojskowa 6/B02  
60 792 Poznań  
Lenkija  
Tel.: +48 516 052 508  
[PhV@dopharma.pl](mailto:PhV@dopharma.pl)

##### **Република България**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
Нидерландия  
Tel. +31-162-582000  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

##### **Luxembourg/Luxemburg**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
Pays-Bas  
Tel: +32 475 367 776  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

##### **Česká republika**

Cymedica, spol. s r.o.  
Pod Nádražím 308/24  
CZ 268 01 Hořovice  
Tel: +420 311 706 211  
[farmakovigilance@cymedica.com](mailto:farmakovigilance@cymedica.com)

##### **Magyarország**

Dopharma Vet S.R.L.  
Str. Aeroport nr. 44  
Localitatea Ghiroda  
Județul Timiș 307200  
România  
Tel: +40 728 138 903  
[a.ardelean@dopharma.ro](mailto:a.ardelean@dopharma.ro)

**Danmark**

Salfarm Danmark A/S  
Nordager 19  
DK- 6000 Kolding  
Tlf: +45 7550 8080  
[info@salfarm.com](mailto:info@salfarm.com)

**Deutschland**

Dopharma Deutschland GmbH  
Hansestr. 53  
DE-48165 Münster  
Tel: +49 (0)2501 594 349 20  
[pharmakovigilanz@dopharma.de](mailto:pharmakovigilanz@dopharma.de)

**Eesti**

Dopharma Polska  
ul. Wojskowa 6/B02  
60 792 Poznań  
Poola  
Tel.: +48 516 052 508  
[PhV@dopharma.pl](mailto:PhV@dopharma.pl)

**Ελλάδα**

Neocell EΠE  
10ο χλμ. Εθνικής Οδού Αθηνών-Λαμίας  
EL-14451 Μεταμόρφωση Αττικής  
Τηλ: +30 210 2844333  
[pharmacovigilance@neocell.gr](mailto:pharmacovigilance@neocell.gr)

**España**

Dopharma Iberia  
Avenida de la Llana 123  
ES-08191, Rubí – Barcelona  
Tel: +34 637 370492  
[farmacovigilancia@dopharma-iberia.com](mailto:farmacovigilancia@dopharma-iberia.com)

**France**

Laboratoire LCV  
Z.I. Plessis Beucher  
FR-35220 Châteaubourg  
Tél: +33 2 99 00 92 92

**Malta**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
L-Olanda  
Tel. +31-162-582000  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

**Nederland**

Dopharma Research B.V.  
Zalmweg 24  
NL-4941 VX Raamsdonksveer  
Tel. +31-162-582000  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

**Norge**

Salfarm Scandinavia AS  
Fridtjof Nansens Plass 4  
N-0160 Oslo  
Tlf: +47 902 97 102  
[norge@salfarm.com](mailto:norge@salfarm.com)

**Österreich**

Dopharma Deutschland GmbH  
Hansestr. 53  
48165 Münster  
Deutschland  
Tel: +49 (0)2501 594 349 20  
[pharmakovigilanz@dopharma.de](mailto:pharmakovigilanz@dopharma.de)

**Polska**

Dopharma Polska  
ul. Wojskowa 6/B02  
PL – 60 792 Poznań  
Tel.: +48 516 052 508  
[PhV@dopharma.pl](mailto:PhV@dopharma.pl)

**Portugal**

VETLIMA-Sociedade Distribuidora de Produtos  
Agro-Pecuários, S.A.  
Centro Empresarial da Rainha, Lote 27  
PT-2050-501 Vila Nova da Rainha  
Tel: +351 263 406 570

Detalhes de contacto para comunicar suspeitas  
de eventos adversos:

[farmacovigilancia@vetlima.com](mailto:farmacovigilancia@vetlima.com)  
Tel: +351 964404163

**Hrvatska**

Arnika Veterina d.o.o.  
Vidikovac 20  
HR-10000 Zagreb  
Tel +385 91 364 3731  
[visnja.pintar-alicevic@arnika-veterina.hr](mailto:visnja.pintar-alicevic@arnika-veterina.hr)

**Ireland**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
The Netherlands  
Tel. +31-162-582000  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

**Ísland**

Salfarm Danmark A/S  
Nordager 19  
6000 Kolding  
Danmörk  
Tlf: +45 75 50 80 80  
[info@salfarm.com](mailto:info@salfarm.com)

**Italia**

Dopharma Italia S.R.L.  
Via delle Porte Nuove, 20  
IT-50144 Firenze  
Tel +39 (346) 14 26 164  
[servizioclienti@dopharma.it](mailto:servizioclienti@dopharma.it)

**Κύπρος**

Neocell ΕΠΕ  
10ο χλμ. Εθνικής Οδού Αθηνών-Λαμίας  
14451 Μεταμόρφωση Αττικής  
Ελλάδα  
Τηλ: +30 210 2844333  
[pharmacovigilance@neocell.gr](mailto:pharmacovigilance@neocell.gr)

**Latvija**

Dopharma Polska  
ul. Wojskowa 6/B02  
60 792 Poznań  
Polija  
Tel.: +48 516 052 508  
[PhV@dopharma.pl](mailto:PhV@dopharma.pl)

**România**

Dopharma Vet S.R.L.  
Str. Aeroport nr. 44  
Localitatea Ghiroda  
RO-Județul Timiș 307200  
Tel: +40 728 138 903  
[a.ardelean@dopharma.ro](mailto:a.ardelean@dopharma.ro)

**Slovenija**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
Nizozemska  
Tel. +31-162-582000  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

**Slovenská republika**

Cymedica, spol. s r.o.  
Pod Nádražím 308/24  
268 01 Hořovice  
Česká republika  
Tel: +420 311 706 211  
[farmakovigilance@cymedica.com](mailto:farmakovigilance@cymedica.com)

**Suomi/Finland**

FaunaPharma Oy  
c/o Oriola Finland Oy  
PL 8  
FI-02101 ESPOO  
Puh: +358 10 375 3050  
[info@faunapharma.fi](mailto:info@faunapharma.fi)

**Sverige**

Salfarm Scandinavia AB  
Florettgatan 29C  
2. Vån  
SE-254 67 Helsingborg  
Tel: +46 (0)767 834 810  
[scan@salfarm.com](mailto:scan@salfarm.com)

**United Kingdom (Northern Ireland)**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
The Netherlands  
Tel. +31-162-582000  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

## PACKAGE LEAFLET

### 1. Name of the veterinary medicinal product

Melovem 15 mg/ml oral suspension for horses

### 2. Composition

Each ml contains:

**Active substances:**

Meloxicam 15 mg

**Excipients:**

Sodium benzoate 1.5 mg

Yellow, aqueous suspension.

### 3. Target species

Horses.

### 4. Indications for use

Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses.

### 5. Contraindications

Do not use in pregnant or lactating mares.

Do not use in horses suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.

Do not use in horses less than 6 weeks of age.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

### 6. Special warnings

Special precautions for safe use in the target species:

Avoid use in any dehydrated, hypovolaemic or hypotensive animals as there is a potential risk of renal toxicity.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

This product can cause eye irritation. In case of contact with the eyes, immediately rinse thoroughly with water.

Pregnancy and lactation:



Laboratory studies in cattle have not produced any evidence for teratogenic, foetotoxic, or maternotoxic effects. However, no data have been generated in horses. Therefore, the use in this species is not recommended during pregnancy and lactation.

**Interaction with other medicinal products and other forms of interaction:**

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.

**Overdose:**

In the case of overdose symptomatic treatment should be initiated.

**7. Adverse events**

Horses:

Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Diarrhoea <sup>1</sup> , appetite loss, lethargy, abdominal pain, colitis, urticaria (hives). Anaphylactoid reactions <sup>2</sup>
---	--

<sup>1</sup> Reversible.

<sup>2</sup> May be serious (including fatal) and should be treated symptomatically.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or its local representative using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

**8. Dosage for each species, routes and method of administration**

To be administered either mixed with food or directly into the mouth at a dosage of 0.6 mg meloxicam/kg body weight (i.e. 4 ml/100 kg body weight), once daily, up to 14 days.

**9. Advice on correct administration**

In case the product is mixed with food, it should be added to a small quantity of food, prior to feeding. The suspension should be given using the measuring syringe provided in the package. The syringe has a kg-body weight scale.

After administration of the veterinary medicinal product, close the bottle by replacing the cap, wash the measuring syringe with warm water and let it dry.

Shake well before use.

Avoid introduction of contamination during use.

**10. Withdrawal periods**

Meat and offal: 3 days.

Not authorised for use in animals producing milk for human consumption.

**11. Special storage precautions**

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

Shelf life after first opening the immediate packaging: 6 months if stored below 25 °C.

## **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

## **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

## **14. Marketing authorisation numbers and pack sizes**

EU/2/09/098/008

EU/2/09/098/009

EU/2/09/098/010

Cardboard box with 1 bottle of 100 ml.

Bottle of 250 ml or 500 ml.

Not all pack sizes may be marketed.

## **15. Date on which the package leaflet was last revised**

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

## **16. Contact details**

Marketing authorisation holder and contact details to report suspected adverse events:

Dopharma Research B.V.

Zalmweg 24

NL-4941 VX Raamsdonksveer

Tel: + 31-162-582000

pharmacovigilance@dopharma.com

Manufacturer responsible for batch release:

Dopharma B.V.

Zalmweg 24

Local representative and contact details to report suspected adverse events:

**België/Belgique/Belgien**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
Nederland/Pays-Bas  
Tel: +32 475 367 776  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

**Република България**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
Нидерландия  
Tel. +31-162-582000  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

**Česká republika**

Cymedica, spol. s r.o.  
Pod Nádražím 308/24  
CZ 268 01 Hořovice  
Tel: +420 311 706 211  
[farmakovigilance@cymedica.com](mailto:farmakovigilance@cymedica.com)

**Danmark**

Salfarm Danmark A/S  
Nordager 19  
DK- 6000 Kolding  
Tlf: +45 7550 8080  
[info@salfarm.com](mailto:info@salfarm.com)

**Deutschland**

Dopharma Deutschland GmbH  
Hansestr. 53  
DE-48165 Münster  
Tel: +49 (0)2501 594 349 20  
[pharmakovigilanz@dopharma.de](mailto:pharmakovigilanz@dopharma.de)

**Eesti**

Dopharma Polska  
ul. Wojskowa 6/B02  
60 792 Poznań  
Polija  
Tel.: +48 516 052 508  
[PhV@dopharma.pl](mailto:PhV@dopharma.pl)

**Lietuva**

Dopharma Polska  
ul. Wojskowa 6/B02  
60 792 Poznań  
Polija  
Tel.: +48 516 052 508  
[PhV@dopharma.pl](mailto:PhV@dopharma.pl)

**Luxembourg/Luxemburg**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
Pays-Bas  
Tel: +32 475 367 776  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

**Magyarország**

Dopharma Vet S.R.L.  
Str. Aeroport nr. 44  
Localitatea Ghiroda  
Județul Timiș 307200  
România  
Tel: +40 728 138 903  
[a.ardelean@dopharma.ro](mailto:a.ardelean@dopharma.ro)

**Malta**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
L-Olanda  
Tel. +31-162-582000  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

**Nederland**

Dopharma Research B.V.  
Zalmweg 24  
NL-4941 VX Raamsdonksveer  
Tel. +31-162-582000  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

**Norge**

Salfarm Scandinavia AS  
Fridtjof Nansens Plass 4  
N-0160 Oslo  
Tlf: +47 902 97 102  
[norge@salfarm.com](mailto:norge@salfarm.com)

**Ελλάδα**

Neocell ΕΠΕ  
10ο χλμ. Εθνικής Οδού Αθηνών-Λαμίας  
EL-14451 Μεταμόρφωση Αττικής  
Τηλ: +30 210 2844333  
[pharmacovigilance@neocell.gr](mailto:pharmacovigilance@neocell.gr)

**España**

Dopharma Iberia  
Avenida de la Llana 123  
ES-08191, Rubí – Barcelona  
Tel: +34 637 370492  
[farmacovigilancia@dopharma-iberia.com](mailto:farmacovigilancia@dopharma-iberia.com)

**France**

Dopharma France S.A.S.  
23 Rue du Prieuré, Saint-Herblon  
FR-44150 Vair-sur-Loire  
Tél: +33 (0)6 99 29 27 43  
[pharmacovigilance@dopharma-france.com](mailto:pharmacovigilance@dopharma-france.com)

**Hrvatska**

Arnika Veterina d.o.o.  
Vidikovac 20  
HR-10000 Zagreb  
Tel +385 91 364 3731  
[visnja.pintar-alicevic@arnika-veterina.hr](mailto:visnja.pintar-alicevic@arnika-veterina.hr)

**Ireland**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
The Netherlands  
Tel. +31-162-582000  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

**Ísland**

Salfarm Danmark A/S  
Nordager 19  
6000 Kolding  
Danmörk  
Tlf: +45 75 50 80 80  
[info@salfarm.com](mailto:info@salfarm.com)

**Österreich**

Dopharma Deutschland GmbH  
Hansestr. 53  
48165 Münster  
Deutschland  
Tel: +49 (0)2501 594 349 20  
[pharmakovigilanz@dopharma.de](mailto:pharmakovigilanz@dopharma.de)

**Polska**

Dopharma Polska  
ul. Wojskowa 6/B02  
PL – 60 792 Poznań  
Tel.: +48 516 052 508  
[PhV@dopharma.pl](mailto:PhV@dopharma.pl)

**Portugal**

VETLIMA-Sociedade Distribuidora de Produtos  
Agro-Pecuários, S.A.  
Centro Empresarial da Rainha, Lote 27  
PT-2050-501 Vila Nova da Rainha  
Tel: +351 263 406 570

Detalhes de contacto para comunicar suspeitas  
de eventos adversos:

[farmacovigilancia@vetlima.com](mailto:farmacovigilancia@vetlima.com)  
Tel: +351 964404163

**România**

Dopharma Vet S.R.L.  
Str. Aeroport nr. 44  
Localitatea Ghiroda  
RO-Județul Timiș 307200  
Tel: +40 728 138 903  
[a.ardelean@dopharma.ro](mailto:a.ardelean@dopharma.ro)

**Slovenija**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
Nizozemska  
Tel. +31-162-582000  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)

**Slovenská republika**

Cymedica, spol. s r.o.  
Pod Nádražím 308/24  
268 01 Hořovice  
Česká republika  
Tel: +420 311 706 211  
[farmakovigilance@cymedica.com](mailto:farmakovigilance@cymedica.com)

**Italia**

Dopharma Italia S.R.L.  
Via delle Porte Nuove, 20  
IT-50144 Firenze  
Tel +39 (346) 14 26 164  
[servizioclienti@dopharma.it](mailto:servizioclienti@dopharma.it)

**Κύπρος**

Neocell ΕΠΕ  
10ο χλμ. Εθνικής Οδού Αθηνών-Λαμίας  
14451 Μεταμόρφωση Αττικής  
Ελλάδα  
Τηλ: +30 210 2844333  
[pharmacovigilance@neocell.gr](mailto:pharmacovigilance@neocell.gr)

**Latvija**

Dopharma Polska  
ul. Wojskowa 6/B02  
60 792 Poznań  
Polija  
Tel.: +48 516 052 508  
[PhV@dopharma.pl](mailto:PhV@dopharma.pl)

**Suomi/Finland**

FaunaPharma Oy  
c/o Oriola Finland Oy  
PL 8  
FI-02101 ESPOO  
Puh: +358 10 375 3050  
[info@faunapharma.fi](mailto:info@faunapharma.fi)

**Sverige**

Salfarm Scandinavia AB  
Florettgatan 29C  
2. Vån  
SE-254 67 Helsingborg  
Tel: +46 (0)767 834 810  
[scan@salfarm.com](mailto:scan@salfarm.com)

**United Kingdom (Northern Ireland)**

Dopharma Research B.V.  
Zalmweg 24  
4941 VX Raamsdonksveer  
The Netherlands  
Tel. +31-162-582000  
[pharmacovigilance@dopharma.com](mailto:pharmacovigilance@dopharma.com)